Cargando…

Potential impact of host immunity on malaria treatment outcome in Tanzanian children infected with Plasmodium falciparum

BACKGROUND: In malaria endemic areas children may recover from malaria after chemotherapy in spite of harbouring genotypically drug-resistant Plasmodium falciparum. This phenomenon suggests that there is a synergy between drug treatment and acquired immunity. This hypothesis was examined in an area...

Descripción completa

Detalles Bibliográficos
Autores principales: Enevold, Anders, Nkya, Watoky MMM, Theisen, Michael, Vestergaard, Lasse S, Jensen, Anja TR, Staalsoe, Trine, Theander, Thor G, Bygbjerg, Ib C, Alifrangis, Michael
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2206045/
https://www.ncbi.nlm.nih.gov/pubmed/18021388
http://dx.doi.org/10.1186/1475-2875-6-153
_version_ 1782148436918796288
author Enevold, Anders
Nkya, Watoky MMM
Theisen, Michael
Vestergaard, Lasse S
Jensen, Anja TR
Staalsoe, Trine
Theander, Thor G
Bygbjerg, Ib C
Alifrangis, Michael
author_facet Enevold, Anders
Nkya, Watoky MMM
Theisen, Michael
Vestergaard, Lasse S
Jensen, Anja TR
Staalsoe, Trine
Theander, Thor G
Bygbjerg, Ib C
Alifrangis, Michael
author_sort Enevold, Anders
collection PubMed
description BACKGROUND: In malaria endemic areas children may recover from malaria after chemotherapy in spite of harbouring genotypically drug-resistant Plasmodium falciparum. This phenomenon suggests that there is a synergy between drug treatment and acquired immunity. This hypothesis was examined in an area of moderately intense transmission of P. falciparum in Tanzania during a drug trail with sulphadoxine-pyrimethamine (SP) or amodiaquine (AQ). METHODS: One hundred children with uncomplicated malaria were treated with either SP or AQ and followed for 28 days. Mutations in parasite genes related to SP and AQ-resistance as well as human sickle cell trait and alpha-thalassaemia were determined using PCR and sequence-specific oligonucleotide probes and enzyme-linked immunosorbent assay (SSOP-ELISA), and IgG antibody responses to a panel of P. falciparum antigens were assessed and related to treatment outcome. RESULTS: Parasitological or clinical treatment failure (TF) was observed in 68% and 38% of children receiving SP or AQ, respectively. In those with adequate clinical and parasitological response (ACPR) compared to children with TF, and for both treatment regimens, prevalence and levels of anti-Glutamate-rich Protein (GLURP)-specific IgG antibodies were significantly higher (P < 0.001), while prevalence of parasite haplotypes associated with SP and AQ resistance was lower (P = 0.02 and P = 0.07, respectively). Interestingly, anti-GLURP-IgG antibodies were more strongly associated with treatment outcome than parasite resistant haplotypes, while the IgG responses to none of the other 11 malaria antigens were not significantly associated with ACPR. CONCLUSION: These findings suggest that GLURP-specific IgG antibodies in this setting contribute to clearance of drug-resistant infections and support the hypothesis that acquired immunity enhances the clinical efficacy of drug therapy. The results should be confirmed in larger scale with greater sample size and with variation in transmission intensity.
format Text
id pubmed-2206045
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-22060452008-01-18 Potential impact of host immunity on malaria treatment outcome in Tanzanian children infected with Plasmodium falciparum Enevold, Anders Nkya, Watoky MMM Theisen, Michael Vestergaard, Lasse S Jensen, Anja TR Staalsoe, Trine Theander, Thor G Bygbjerg, Ib C Alifrangis, Michael Malar J Research BACKGROUND: In malaria endemic areas children may recover from malaria after chemotherapy in spite of harbouring genotypically drug-resistant Plasmodium falciparum. This phenomenon suggests that there is a synergy between drug treatment and acquired immunity. This hypothesis was examined in an area of moderately intense transmission of P. falciparum in Tanzania during a drug trail with sulphadoxine-pyrimethamine (SP) or amodiaquine (AQ). METHODS: One hundred children with uncomplicated malaria were treated with either SP or AQ and followed for 28 days. Mutations in parasite genes related to SP and AQ-resistance as well as human sickle cell trait and alpha-thalassaemia were determined using PCR and sequence-specific oligonucleotide probes and enzyme-linked immunosorbent assay (SSOP-ELISA), and IgG antibody responses to a panel of P. falciparum antigens were assessed and related to treatment outcome. RESULTS: Parasitological or clinical treatment failure (TF) was observed in 68% and 38% of children receiving SP or AQ, respectively. In those with adequate clinical and parasitological response (ACPR) compared to children with TF, and for both treatment regimens, prevalence and levels of anti-Glutamate-rich Protein (GLURP)-specific IgG antibodies were significantly higher (P < 0.001), while prevalence of parasite haplotypes associated with SP and AQ resistance was lower (P = 0.02 and P = 0.07, respectively). Interestingly, anti-GLURP-IgG antibodies were more strongly associated with treatment outcome than parasite resistant haplotypes, while the IgG responses to none of the other 11 malaria antigens were not significantly associated with ACPR. CONCLUSION: These findings suggest that GLURP-specific IgG antibodies in this setting contribute to clearance of drug-resistant infections and support the hypothesis that acquired immunity enhances the clinical efficacy of drug therapy. The results should be confirmed in larger scale with greater sample size and with variation in transmission intensity. BioMed Central 2007-11-16 /pmc/articles/PMC2206045/ /pubmed/18021388 http://dx.doi.org/10.1186/1475-2875-6-153 Text en Copyright © 2007 Enevold et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Enevold, Anders
Nkya, Watoky MMM
Theisen, Michael
Vestergaard, Lasse S
Jensen, Anja TR
Staalsoe, Trine
Theander, Thor G
Bygbjerg, Ib C
Alifrangis, Michael
Potential impact of host immunity on malaria treatment outcome in Tanzanian children infected with Plasmodium falciparum
title Potential impact of host immunity on malaria treatment outcome in Tanzanian children infected with Plasmodium falciparum
title_full Potential impact of host immunity on malaria treatment outcome in Tanzanian children infected with Plasmodium falciparum
title_fullStr Potential impact of host immunity on malaria treatment outcome in Tanzanian children infected with Plasmodium falciparum
title_full_unstemmed Potential impact of host immunity on malaria treatment outcome in Tanzanian children infected with Plasmodium falciparum
title_short Potential impact of host immunity on malaria treatment outcome in Tanzanian children infected with Plasmodium falciparum
title_sort potential impact of host immunity on malaria treatment outcome in tanzanian children infected with plasmodium falciparum
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2206045/
https://www.ncbi.nlm.nih.gov/pubmed/18021388
http://dx.doi.org/10.1186/1475-2875-6-153
work_keys_str_mv AT enevoldanders potentialimpactofhostimmunityonmalariatreatmentoutcomeintanzanianchildreninfectedwithplasmodiumfalciparum
AT nkyawatokymmm potentialimpactofhostimmunityonmalariatreatmentoutcomeintanzanianchildreninfectedwithplasmodiumfalciparum
AT theisenmichael potentialimpactofhostimmunityonmalariatreatmentoutcomeintanzanianchildreninfectedwithplasmodiumfalciparum
AT vestergaardlasses potentialimpactofhostimmunityonmalariatreatmentoutcomeintanzanianchildreninfectedwithplasmodiumfalciparum
AT jensenanjatr potentialimpactofhostimmunityonmalariatreatmentoutcomeintanzanianchildreninfectedwithplasmodiumfalciparum
AT staalsoetrine potentialimpactofhostimmunityonmalariatreatmentoutcomeintanzanianchildreninfectedwithplasmodiumfalciparum
AT theanderthorg potentialimpactofhostimmunityonmalariatreatmentoutcomeintanzanianchildreninfectedwithplasmodiumfalciparum
AT bygbjergibc potentialimpactofhostimmunityonmalariatreatmentoutcomeintanzanianchildreninfectedwithplasmodiumfalciparum
AT alifrangismichael potentialimpactofhostimmunityonmalariatreatmentoutcomeintanzanianchildreninfectedwithplasmodiumfalciparum